SCHEMBL5863318

SCHEMBL5863318

CCC(NC(=O)OC(C)(C)C)c1nn2cccc2c(=O)n1Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.52
ALDH1A1 P00352 2/20 0.40
BRD4 O60885 1/20 0.39
SYK P43405 1/20 0.38
ATM Q13315 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
XBP1 P17861 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACE P12821 1/20 0.38
PIK3CD O00329 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863400 0.88 KIF11 (0.49) KIF11BRD4SYKKMT2ATSHR
SCHEMBL5863338 0.87 KIF11 (0.48) KIF11BRD4SYKNPSR1PIK3CD
SCHEMBL5863742 0.86 KIF11 (0.48) KIF11BRD4SYKKMT2ATSHR
SCHEMBL4102984 0.84 KIF11 (0.42) KIF11ALDH1A1BRD4SYKKMT2A
SCHEMBL5863323 0.82 KIF11 (0.62) KIF11
SCHEMBL5863516 0.78 KIF11 (0.68) KIF11
SCHEMBL5863490 0.77 KIF11 (0.51) KIF11PIK3CDPIK3R1
SCHEMBL5863220 0.77 KIF11 (0.56) KIF11ALDH1A1HPGDPIK3CDPIK3R1
SCHEMBL5863326 0.76 KIF11 (0.57) KIF11PIK3CDPIK3R1
SCHEMBL5863767 0.76 KIF11 (0.77) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030118-B2 Pyrrolotriazinone compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US disclosed
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents BRISTOL-MYERS SQUIBB COMPANY 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents CCNB1, NUMA1, CCNA1 KIF11 858/4885ALDH1A1 1027/4885BRD4 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.